2022
DOI: 10.1101/2022.12.10.519855
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies

Abstract: There are no therapeutic predictive biomarkers or representative preclinical models for high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), a highly aggressive, fatal, and heterogeneous epithelial malignancy. We established patient-derived (PD) tumoroids from biobanked tissue samples of advanced high-grade GEP-NEN patients and used this model for targeted ex vivo pharmacotyping, next-generation sequencing, and perturbational profiling. We used tissue-matched PD tumoroids to profile individual… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 57 publications
0
2
0
Order By: Relevance
“…Finally, drug screening applications were demonstrated using paclitaxel, everolimus, and navitoclax, demonstrating the suitability of these PTOs for this application. The second preprint demonstrated the continued work of April-Monn et al on tumoroids [177]. The group would create three new PTO sets from pNEN tissues, although a rigorous preselection process was performed beforehand.…”
Section: Ecm-supported Constructsmentioning
confidence: 99%
See 1 more Smart Citation
“…Finally, drug screening applications were demonstrated using paclitaxel, everolimus, and navitoclax, demonstrating the suitability of these PTOs for this application. The second preprint demonstrated the continued work of April-Monn et al on tumoroids [177]. The group would create three new PTO sets from pNEN tissues, although a rigorous preselection process was performed beforehand.…”
Section: Ecm-supported Constructsmentioning
confidence: 99%
“…Advances in gene editing, including CRISPR/Cas9, have been utilized in both cell and in frog models of pNENs, creating new molecular model subtypes of previously existing models [36,161,202]. Coupled with more advanced maintenance and establishment techniques, new cell lines and 3D models have shown to be more accurate representations of pNENs than earlier established methods [57,177]. Three-dimensional models are especially promising, creating an accurate tumor model while combining the high-throughput capabilities of cell lines.…”
Section: Future Directionsmentioning
confidence: 99%